Skip Navigation



NDT Advance Access published online on October 23, 2009
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfp568
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mann, J. F.E.
Right arrow Articles by Yusuf, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mann, J. F.E.
Right arrow Articles by Yusuf, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Is therapy of people with chronic kidney disease ONTARGET?

Johannes F.E. Mann, Sheldon Tobe, Koon K. Teo and Salim Yusuf

Population Health Research Institute, McMaster University, Hamilton Canada and Department of Nephrology, Hypertension and Rheumatology, Schwabing General Hospital, Kolner Platz 1, Munchen 80804, Germany

Correspondence and offprint requests to: Correspondence and offprint requests to: Johannes F.E. Mann; E-mail: prof.j.mann@googlemail.com

Keywords: progression of renal disease; acute kidney injury; hyperkalemia; hypertension

The first 150 words of the full text of this article appear below.

The results of the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) study were unexpected, demonstrating no cardiovascular or renal benefit but substantial adverse effects of adding an angiotensin II receptor blocker (ARB), telmisartan 80 mg/day, to an angiotensin-converting enzyme (ACE) inhibitor, ramipril 10 mg/day (‘dual therapy’) vs ramipril alone [1,2]. Those results stirred up a number of commentaries especially from the nephrological community and in most major nephrological journals [3–11]. In this journal, Dr. Abutaleb [10] brings up a number of concerns related to the design and the renal results of ONTARGET, and we will reply to those concerns in the following. From the beginning, we would like to stress that ONTARGET is the only reliable outcome trial at present to build our judgment on dual therapy outside heart failure and one flawed renal study [13,14]. All . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?